Reiterating the strength of its M&A-heavy strategy, Valeant CEO Michael Pearson touted the company's deal record during its second quarter earnings call.
Over the last five years Valeant Pharmaceuticals International Inc. has gone from a small Canadian dermatology company to a large multi-national conglomerate. This transformation was due to CEO Michael Pearson's vision of acquiring growth instead of focusing on in-house R&D.
Since Biovail Corp. bought Valeant in a reverse merger in June 2010, the new iteration of Valeant has been...
The Pink Sheet explores how regulatory approvals for Leqembi differ around the world, and looks at what is coming next.
FDA regulation was painted as an obstacle to US dominance in the cell and gene therapy space even as panelists at an agency event praised the Office of Therapeutic Products' track record under Nicole Verdun.
Expanded funding for cost recovery could dovetail with FDA Commissioner Martin Makary’s idea for a “conditional approval” pathway based on a plausible mechanism of action.
